+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pain Management Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 250 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5987683
The global market for Pain Management Drugs is estimated at US$76.3 Billion in 2023 and is projected to reach US$92.9 Billion by 2030, growing at a CAGR of 2.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the pain management drugs market is driven by several factors. A significant driver is the rising prevalence of chronic pain conditions such as arthritis, back pain, and neuropathic pain, which increases the demand for effective pain management solutions. Advances in drug delivery technologies, including transdermal patches and implantable devices, have expanded the addressable market by offering new ways to administer pain relief. The aging global population also contributes to market growth, as older adults are more likely to suffer from chronic pain conditions. Additionally, increasing awareness and diagnosis of pain-related conditions have propelled market demand.

Regulatory support for the development of new pain management drugs, along with initiatives to combat the opioid crisis by promoting safer alternatives, further stimulates market expansion. Moreover, the growing trend of personalized medicine, which tailors pain management therapies to individual genetic profiles, drives adoption and enhances treatment efficacy. Collectively, these factors are shaping a dynamic and rapidly expanding market for pain management drugs.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Opioid Drugs segment, which is expected to reach US$24.9 Billion by 2030 with a CAGR of a 2.5%. The NSAIDS segment is also set to grow at 2.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $20.8 Billion in 2023, and China, forecasted to grow at an impressive 5.5% CAGR to reach $18.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Pain Management Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pain Management Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Pain Management Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AdvaCare Pharma, Daiichi Sankyo Co., Ld., Eisai Co., Ltd., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

  • AdvaCare Pharma
  • Daiichi Sankyo Co., Ld.
  • Eisai Co., Ltd.
  • Eli Lilly & Company
  • Endo Pharmaceuticals, Inc.
  • Fresenius Kabi USA
  • IBSA Institute Biochimique SA
  • Mallinckrodt Pharmaceuticals
  • Merck & Co. Inc.
  • Neuracle Lifesciences Private Limited
  • Novartis AG
  • Pfizer, Inc.
  • Purdue Pharma L.P.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Pain Management Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Pain Conditions Spurs Demand for Effective Therapies
  • Aging Population Expands Addressable Market Opportunity for Pain Management Drugs
  • Advances in Drug Delivery Technologies Propel Growth in Market Adoption
  • Development of Non-Addictive Painkillers Strengthens Business Case for Safer Alternatives
  • Personalized Medicine and Genetic Testing Drive Adoption of Tailored Pain Therapies
  • Emergence of Biologics and Biosimilars Generates New Market Opportunities
  • Increasing Awareness and Diagnosis of Pain-Related Conditions Accelerates Demand
  • Integration of Multimodal Pain Management Strategies Sustains Growth in Treatment Approaches
  • Here`s How Extended-Release Formulations Enhance Patient Adherence
  • Technological Innovations in Transdermal and Implantable Devices Throw the Spotlight On Advanced Pain Relief Methods
  • Expansion of Healthcare Infrastructure in Emerging Markets Generates Demand for Pain Management Drugs
  • Rising Trend of Non-Pharmacological Interventions in Pain Management Generates Complementary Market Opportunities
  • Increasing Investment in Biotechnology Propels Growth in Novel Pain Therapies
  • Adoption of Telemedicine and Digital Health Technologies Expands Access to Pain Management Solutions
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pain Management Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Pain Management Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Opioid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Opioid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Opioid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for NSAIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for NSAIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for NSAIDS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Non-Narcotic Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Non-Narcotic Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Non-Narcotic Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antimigraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antimigraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Antimigraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Chronic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Chronic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Chronic Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Acute Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Acute Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Acute Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
JAPAN
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
CHINA
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
EUROPE
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Pain Management Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
FRANCE
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
GERMANY
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Pain Management Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Pain Management Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Pain Management Drugs by Drug Type - Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Pain Management Drugs by Drug Type - Percentage Breakdown of Value Sales for Opioid Drugs, NSAIDS, Non-Narcotic Analgesics, Antimigraine Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Pain Management Drugs by Type - Chronic Pain and Acute Pain - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Pain Management Drugs by Type - Chronic Pain and Acute Pain Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Pain Management Drugs by Type - Percentage Breakdown of Value Sales for Chronic Pain and Acute Pain for the Years 2014, 2024 & 2030
AUSTRALIA
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Pain Management Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

  • AdvaCare Pharma
  • Daiichi Sankyo Co., Ld.
  • Eisai Co., Ltd.
  • Eli Lilly & Company
  • Endo Pharmaceuticals, Inc.
  • Fresenius Kabi USA
  • IBSA Institute Biochimique SA
  • Mallinckrodt Pharmaceuticals
  • Merck & Co. Inc.
  • Neuracle Lifesciences Private Limited
  • Novartis AG
  • Pfizer, Inc.
  • Purdue Pharma L.P.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.

Table Information